Q-omics provides the consensus-scored CCL18 profile across patient tissues and cancer cell-line models. CCL18 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CCL18 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, CCL18 RNA expression shows 18,835 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where CCL18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCL18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCL18 survival associations across molecular data types. CCL18 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCL18 RNA expression–survival associations across cancer types. High CCL18 expression shows unfavorable associations in UVM and LUSC, but favorable associations in LIHC, HNSC, KIRP and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CCL18 RNA expression.
This table summarizes CCL18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CCL18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCL18 shows lower tumor expression in BRCA and higher tumor expression in KIRC, HNSC, KIRP, COAD and THCA. The KIRC box plot shows higher CCL18 RNA expression in tumor versus normal tissue (log2 FC = +3.497, t-test p < 0.001).
This table shows molecular features associated with CCL18 in patient tissues and cancer cell lines. In patient samples, CCL18 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCL18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SKIN.
